Kidney Diseases  >>  Soliris (eculizumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

10 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Soliris (eculizumab) / AstraZeneca
aHUS, NCT00844844 / 2008-006953-41: Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant

Completed
2
1
US, Europe
Eculizumab
Alexion Pharmaceuticals
Atypical Hemolytic Uremic Syndrome
09/10
07/13
aHUS, NCT00844545 / 2008-006952-23: Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant

Completed
2
16
US, Europe
Eculizumab
Alexion Pharmaceuticals
Atypical Hemolytic Uremic Syndrome
09/10
07/13
aHUS, NCT00844428 / 2008-006955-28: Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive

Completed
2
5
Canada, Europe
eculizumab
Alexion Pharmaceuticals
Atypical Hemolytic Uremic Syndrome
10/10
12/13
aHUS, NCT00838513 / 2008-006954-17: Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome

Completed
2
15
Canada, Europe
eculizumab
Alexion Pharmaceuticals
Atypical Hemolytic Uremic Syndrome
10/10
12/13
NCT01757431: The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS)

Completed
2
2
Japan
Eculizumab
Alexion Pharmaceuticals
Atypical Hemolytic Uremic Syndrome (aHUS)
09/13
09/13
NCT01194973 / 2010-020326-18: An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome

Completed
2
44
US, Europe
Eculizumab
Alexion Pharmaceuticals
Atypical Hemolytic-Uremic Syndrome
10/13
02/14
aHUS, NCT01193348: An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome

Completed
2
22
US, Canada, Europe, RoW
Eculizumab
Alexion Pharmaceuticals
Atypical Hemolytic-Uremic Syndrome
01/14
04/14
NCT01567085 / 2010-019631-35: Safety & Efficacy Of Eculizumab In The Prevention Of AMR In Sensitized Recipients Of A Kidney Transplant From A Deceased Donor

Completed
2
80
Europe, RoW
Eculizumab, Soliris
Alexion Pharmaceuticals
Stage V Chronic Kidney Disease
06/15
05/17
NCT01756508: Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury

Completed
2
57
RoW
eculizumab, Soliris
Russian Academy of Medical Sciences
End-Stage Renal Disease, Kidney Failure, Graft Reperfusion Injury
04/17
12/17
EAGLE, NCT02093533: Eculizumab in Primary MPGN

Completed
2
10
Europe
Eculizumab, Soliris
Mario Negri Institute for Pharmacological Research, Alexion Pharma Italy s.r.l.
Membranoproliferative Glomerulonephritis
12/17
12/17

Download Options